Designing and Engineering Antibodies to Mutable Protein Targets
April 14, 2019 | World Vaccine Congress
Designing and Engineering Antibodies to Mutable Protein Targets
Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering
April 11, 2019 | PEGS
Pharmacophore-based Protein Surface Patch Searching and Its Application to in silico Antibody Engineering
Antibody Design and Engineering Through Integration of Computational and Experimental Methods
February 26, 2019 | Antibody Engineering & Therapeutics, Asia
Antibody Design and Engineering Through Integration of Computational and Experimental Methods
Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
January 15, 2019 | Peptalk
Improved Computational Modeling of Antibody-Antigen Complexes by Integration of Deep Mutational Scanning Data
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
January 15, 2019 | Peptalk
Structure Guided Optimization of Antibody Fc and Fab Domains for Improved Pharmacokinetic Properties
(Sibeprenlimab), an APRIL-Neutralizing IgG2
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
(Sibeprenlimab), an APRIL-Neutralizing IgG2
Monoclonal Antibody, in Healthy Volunteers
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Monoclonal Antibody, in Healthy Volunteers
Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection
November 13, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
Assessment of Resistance Development to Therapeutic mAb VIS410 in an International Phase 2a Study (VIS410-202) in Adults with Uncomplicated Influenza A Infection
VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy
October 23, 2018 | American Society of Nephrology (ASN)
VIS649 reduces serum IgA levels in NHPs dose dependently: PK/PD exposure-response modeling for translation to treatment of IgA Nephropathy
Preclinical safety and scalability of VIS649 production for clinical trials for the treatment of IgA nephropathy
October 23, 2018 | American Society of Nephrology (ASN)